



001.00254

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Clark et al.)
Serial No.: 10/664,561)
Filed: February 9, 2000)
For: METHODS AND COMPOSITIONS)
FOR FIBROBLAST)
MIGRATION)

)
)
)
)
)
)

Examiner:

Art Unit: 1618

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.97-1.98

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §§1.97-1.98, Applicants hereby bring to the attention of the United States Patent and Trademark Office ("PTO") the references listed on the attached PTO-1449 form. Pursuant to 37 CFR § 1.98(d), because the above-identified patent application claims priority under 35 U.S.C 120 to U.S. Patent Application Serial No. 09/500,512 (the "'512 application") copies of the references are not enclosed because they were provided to the PTO in the '512 application.

Applicants believe no fee is due, however, applicants authorize charging Deposit Account 50-0772 for any fees due.

Respectfully submitted,

July 28, 2005
Date

Karla M. Weyand
Karla M. Weyand
Reg. No. 40,223

Rogalskyj & Weyand, LLP
P.O. Box 44
Livonia, New York 14487-0044
Tel: 716-625-5380
Fax: 716-626-5384

Under the Paperwork Reduction Act of 1995

ersons are required to respond to a collection of information

ss it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Docket Number (Optional) 001.00254	Application Number 10/664,561
Applicant(s) Richard Clark et al.	
Filing Date September 19, 2003	Group Art Unit 1618



Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995:

Persons are required to respond to a collection of information

as it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Docket Number (Optional) 001.00254	Application Number 10/664,561
Applicant(s) Richard Clark et al.	
Filing Date September 19, 2003	Group Art Unit 1618

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	8	Armani et al., BLOOD, 72(3):919-924(1988)	
	9	Brennan, BLOOD REVIEWS, 5:240-244(1991)	
	10	Clark et al., J. INVESTIGATIVE DERMATOLOGY, 79(5); 264-269(1982)	
	11	Epstein et al. , ANN. OTOL. LARYNGOL., 95:40-45(1986)	
	12	Farrugia, et al. TRANSFUSION 32(8):755-759(1992)	
	13	Finnlayson et al., BIOCHEMISTRY, 2(1):42-46(1963)	
	14	Galanakis, THROMBOSIS RESEARCH, 78(4): 303-313(1995)	
	15	Greiling et al., J. CELL. SCIENCE, 110: 861-870(1997)	
	16	Harker et al., NEW ENGLAND J. MED., 287(20):999-1005(1972)	✓
	17	Kazal et al., P.S.E.M.B., 113:989-994(1963)	
	18	Masri et al., THROMB> HAEMOSTAS, 49:116-119(1983)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995:

Persons are required to respond to a collection of information

unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

3

Docket Number (Optional) 001.00254	Application Number 10/664,561
Applicant(s) Richard Clark et al.	
Filing Date September 19, 2003	Group Art Unit 1618

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	19	Mosesson et al., J. CLIN. INVESTIGATION, 42(6):747-755(1963)	
	20	Mosesson et al., BIOCHEMISTRY, 5(9): 2829-2835(1966)	
	21	Siedentop et al., LARYGOSCOPE, 95:1074-1076(1985)	
	22	Staindi , ANN. OTOL., 88:413-418(1979)	
	23	Stathakis et al., THROMBOSIS RESEARCH 13:467-475(1978)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.